These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38977151)

  • 1. Real-World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study.
    Jung H; Kim S; Lee CS; Byeon SH; Kim SS; Lee SW; Kim YJ
    Am J Ophthalmol; 2024 Nov; 267():142-152. PubMed ID: 38977151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
    Cancer Lett; 2024 Aug; 596():216998. PubMed ID: 38830470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Sada I; Harada Y; Hiyama T; Mizukami M; Kan T; Kawai M; Kiuchi Y
    Melanoma Res; 2023 Dec; 33(6):539-546. PubMed ID: 37788106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
    Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
    Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
    Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
    J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
    Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
    Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Noninfectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database.
    Sobrin L; Yu Y; Susarla G; Chan W; Xia T; Kempen JH; Hubbard RA; VanderBeek BL
    Ophthalmology; 2020 Nov; 127(11):1558-1566. PubMed ID: 32353382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
    Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
    J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases.
    Fujisawa Y; Ito T; Kato H; Irie H; Kaji T; Maekawa T; Asai J; Yamamoto Y; Fujimura T; Nakai Y; Yasuda M; Matsuyama K; Muto I; Matsushita S; Uchi H; Nakamura Y; Uehara J; Yoshino K
    Eur J Cancer; 2021 Mar; 145():210-220. PubMed ID: 33503528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
    Fan Q; Chen H; Hu Y; Zhao B
    Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
    Nanda JK; Dusza SW; Navarrete-Dechent C; Liopyris K; Marghoob AA; Marchetti MA
    JAMA Dermatol; 2021 Jan; 157(1):79-83. PubMed ID: 32936222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
    Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.